Journal
CELLULAR AND MOLECULAR NEUROBIOLOGY
Volume 41, Issue 2, Pages 199-227Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10571-020-00849-8
Keywords
Parkinson's disease; PARK17; VPS35; Retromer complex
Categories
Funding
- none [-] Funding Source: Medline
Ask authors/readers for more resources
Mutations in the VPS35 gene have been linked to late-onset familial Parkinson's disease, potentially affecting lysosomal and autophagy function, mitochondrial homeostasis, neurotransmission, and interacting with other genes associated with PD such as alpha-SYNUCLEIN, PARKIN, and LRRK2.
The vacuolar protein sorting 35 (VPS35) gene located on chromosome 16 has recently emerged as a cause of late-onset familial Parkinson's disease (PD) (PARK17). The gene encodes a 796-residue protein nearly ubiquitously expressed in human tissues. The protein localizes on endosomes where it assembles with other peripheral membrane proteins to form the retromer complex. How VPS35 mutations induce dopaminergic neuron degeneration in humans is still unclear. Because the retromer complex recycles the receptors that mediate the transport of hydrolase to lysosome, it has been suggested that VPS35 mutations lead to impaired lysosomal and autophagy function. Recent studies also demonstrated that VPS35 and the retromer complex influence mitochondrial homeostasis, suggesting that VPS35 mutations elicit mitochondrial dysfunction. More recent studies have identified a key role of VPS35 in neurotransmission, whilst others reported a functional interaction between VPS35 and other genes associated with familial PD, including alpha-SYNUCLEIN-PARKIN-LRRK2. Here, we review the biological role of VPS35 protein, the VPS35 mutations identified in human PD patients, and the potential molecular mechanism by which VPS35 mutations can induce progressive neurodegeneration in PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available